Evidence map›Paper›PMID 34570349›Full record

ArticleTranslational stroke research2022

Functional Assessment of Stroke-Induced Regulation of miR-20a-3p and Its Role as a Neuroprotectant.

Taylor E Branyan, Amutha Selvamani, Min Jung Park, Kriti E Korula, Kelby F Kosel, Rahul Srinivasan, Farida Sohrabji

Open access · hybridAbstract read
In one paragraph

Article in Translational stroke research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Taylor E Branyan *Women's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Amutha Selvamani *Women's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Min Jung ParkWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Kriti E KorulaWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Kelby F KoselWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Rahul SrinivasanWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA.
Farida SohrabjiWomen's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, Texas A&M Health Science Center College of Medicine, Bryan, TX, 77807, USA. f-sohrabji@tamu.edu.ORCID http://orcid.org/0000-0002-6960-3411
Texas A&M Health Science Center · USTexas A&M Health Science Center · US

Funding

Epigenetics of the Aging Astrocyte: Implications for StrokeR01AG042189 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Farida Sohrabji · 2011 to 2026
$3.1M
Epigenetics of the Aging Astrocyte: Implications for StrokeRF1AG042189 · NIA · TEXAS A&M UNIVERSITY · PI SOHRABJI, FARIDA · 2018 to 2018
$2.8M
Targeting the gut for stroke neuroprotection; IGF-1 modulation of the blood-gut barrierRF1NS119872 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI BAKE, SHAMEENA, SOHRABJI, FARIDA · 2022 to 2022
$1.7M
Role of Astrocytic miR-20a-3p as a Potential Therapeutic for Ischemic StrokeF31NS118970 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI BRANYAN, TAYLOR · 2021 to 2023
$106k
NIA NIH HHS RF1 AG042189NIA NIH HHS RFAG042189NINDS NIH HHS 1F31NS118970NINDS NIH HHS F31 NS118970NINDS NIH HHS RF1 NS119872
6 · The paper itself

Abstract

MicroRNAs have gained popularity as a potential treatment for many diseases, including stroke. This study identifies and characterizes a specific member of the miR-17-92 cluster, miR-20a-3p, as a possible stroke therapeutic. A comprehensive microRNA screening showed that miR-20a-3p was significantly upregulated in astrocytes of adult female rats, which typically have better stroke outcomes, while it was profoundly downregulated in astrocytes of middle-aged females and adult and middle-aged males, groups that typically have more severe stroke outcomes. Assays using primary human astrocytes and neurons show that miR-20a-3p treatment alters mitochondrial dynamics in both cell types. To assess whether stroke outcomes could be improved by elevating astrocytic miR-20a-3p, we created a tetracycline (Tet)-induced recombinant adeno-associated virus (rAAV) construct where miR-20a-3p was located downstream a glial fibrillary acidic protein promoter. Treatment with doxycycline induced miR-20-3p expression in astrocytes, reducing mortality and modestly improving sensory motor behavior. A second Tet-induced rAAV construct was created in which miR-20a-3p was located downstream of a neuron-specific enolase (NSE) promoter. These experiments demonstrate that neuronal expression of miR-20a-3p is vastly more neuroprotective than astrocytic expression, with animals receiving the miR-20a-3p vector showing reduced infarction and sensory motor improvement. Intravenous injections, which are a therapeutically tractable treatment route, with miR-20a-3p mimic 4 h after middle cerebral artery occlusion (MCAo) significantly improved stroke outcomes including infarct volume and sensory motor performance. Improvement was not observed when miR-20a-3p was given immediately or 24 h after MCAo, identifying a unique delayed therapeutic window. Overall, this study identifies a novel neuroprotective microRNA and characterizes several key pathways by which it can improve stroke outcomes.

Indexed as

MicroRNAsStrokeAnimalsDisease Models, AnimalFemaleInfarction, Middle Cerebral ArteryMaleNeuroprotectionRatsMicroRNAsMIRN20 microRNA, ratAstrocyteBlood–brain barrierIschemic strokeMatrix metalloproteinasesMicroRNAMitochondria

Identifiers

PMID34570349
PMCPMC9046320
OpenAlexW3203753694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.